Related Experiment Video
Updated: Mar 13, 2026

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study
Published on: March 22, 2024
Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells
Yun-Fang Zhen1, Song-Tao Li2, Yun-Rong Zhu3
1The Center of Diagnosis and Treatment for Children's Bone Diseases, The Children's Hospital Affiliated to Soochow University, Suzhou, China.
Abstract:
Malignant osteosarcoma (OS) is still a deadly disease for many affected patients. The search for the novel anti-OS agent is extremely urgent and important. Our previous study has proposed that salinomycin is a novel anti-OS agent. Here we characterized DNA-dependent protein kinase catalytic subunit (DNA-PKcs) as a primary salinomycin resistance factor in OS cells. DNA-PKcs inhibitors (NU7026, NU7441 and LY294002) or DNA-PKcs shRNA knockdown dramatically potentiated salinomycin-induced death and apoptosis of OS cells (U2OS and MG-63 lines). Further, forced-expression of microRNA-101 ("miR-101") downregulated DNA-PKcs and augmented salinomycin's cytotoxicity against OS cells. Reversely, over-expression of DNA-PKcs in OS cells inhibited salinomycin's lethality. For the mechanism study, we show that DNA-PKcs is required for salinomycin-induced pro-survival autophagy activation. DNA-PKcs inhibition (by NU7441), shRNA knockdown or miR-101 expression inhibited salinomycin-induced Beclin-1 expression and autophagy induction. Meanwhile, knockdown of Beclin-1 by shRNA significantly sensitized salinomycin-induced OS cell lethality. In vivo, salinomycin administration suppressed U2OS xenograft tumor growth in severe combined immuno-deficient (SCID) mice, and its anti-tumor activity was dramatically potentiated with co-administration of the DNA-PKcs inhibitor NU7026. Together, these results suggest that DNA-PKcs could be a primary resistance factor of salinomycin in OS cells. DNA-PKcs inhibition or silence may thus significantly increase salinomycin's sensitivity in OS cells.
Insights
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) drives resistance to salinomycin in osteosarcoma. Inhibiting DNA-PKcs enhances salinomycin
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Osteosarcoma (OS) remains a significant challenge, necessitating novel therapeutic agents.
- Salinomycin has emerged as a potential anti-OS agent.
- Understanding resistance mechanisms is crucial for optimizing OS treatment.
Purpose of the Study:
- To identify key factors mediating resistance to salinomycin in osteosarcoma cells.
- To investigate the role of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) in salinomycin resistance.
- To explore therapeutic strategies combining salinomycin with DNA-PKcs inhibition.
Main Methods:
- Utilized osteosarcoma cell lines (U2OS, MG-63) and in vivo xenograft models.
- Employed DNA-PKcs inhibitors (NU7026, NU7441, LY294002), shRNA knockdown, and microRNA-101 (miR-101) expression.
- Assessed cell death, apoptosis, autophagy markers (Beclin-1), and tumor growth.
Main Results:
- DNA-PKcs was identified as a primary salinomycin resistance factor in OS cells.
- Inhibition or knockdown of DNA-PKcs potentiated salinomycin-induced cell death and apoptosis.
- DNA-PKcs inhibition suppressed salinomycin-induced pro-survival autophagy.
- Combined salinomycin and DNA-PKcs inhibitor treatment reduced tumor growth in vivo.
Conclusions:
- DNA-PKcs is a critical mediator of salinomycin resistance in osteosarcoma.
- Targeting DNA-PKcs can overcome salinomycin resistance and enhance its anti-tumor efficacy.
- Combination therapy with salinomycin and DNA-PKcs inhibitors holds promise for osteosarcoma treatment.
Related Concept Videos
Treatment Resistant Cancers
Abnormal Proliferation

